When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GRCL - Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1
Gracell Biotechnologies Inc.
BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement.
Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech in a deal that has a potential value of $920 million.
Gracell Biotech was approved to start a China Phase I/II clinical trial of its allogeneic donor-derived CD19 CAR-T cell therapy.